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Abstract Epilepsy in people with intellectual disability is more than the sum of the two 
conditions. Diagnosis is challenging in the face of cognitive and communication 
difficulties and in some instances the need to rely on third party information 
and difficulties in accessing relevant investigations. Treatment is complicated 
by the lack of evidence specific to intellectual disability and associated 
neurodevelopmental comorbidities. The presence in many with associated 
physical and psychological co-morbidity in the face of treatment resistance 
and increased preponderance to side effects and challenging behavior makes 
epilepsy management in people with intellectual disability highly complex. 
It can be argued that specific understanding and skill sets are needed to help 
manage this vulnerable group. This book chapter looks to outline the unique 
challenges and questions to treatment this special population poses and looks 
to provide evidence based up to date answers where available.
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Epilepsy is a chronic disorder of the brain characterized by a predisposition to sei-
zure activity, and associated with long term neurobiological, psychological, and 
social effects. A seizure can be defined as a transient occurrence of neurological 
symptoms associated with abnormal neuronal activity in the brain. The semiology 
of the seizure event will vary dependent upon the origin of the abnormal or exces-
sive neuronal activity and may present with sensory, motor, emotional, or behav-
ioral disturbance [1]. Two unproved seizures with at least a day apart were needed 
to diagnose epilepsy but The International League against Epilepsy (ILAE) Task 
Force has since refined this definition. Now clinicians are advised to consider an 
epilepsy diagnosis in individuals with one unprovoked seizure in association with 
other known risk factors [2].
10.2  Classification
The new Classification of the Epilepsies developed by the ILAE Commission 
for Classification and Terminology proposes a multilevel classification system. 




















resources), while considering etiology of the epilepsy throughout the assess-
ment process [3] (Table 10.1).
 1. Seizure Type—seizures are classified focal, generalized, and unknown onset.
 2. Epilepsy type—as well as the seizure types above, good practice now considers 
combined generalized and focal epilepsy. Such diagnoses are likely to require 
investigations including characteristic findings on electroencephalogram (EEG).
 3. Epilepsy syndrome—Cluster of symptoms including clinical history, seizure 
type, EEG changes, typical findings on neuroimaging (MRI), and genetic 
testing.
10.3  Epidemiology
The estimated prevalence of epilepsy in the general population may be anywhere 
between 0.6 and 1% [5]. In comparison, the prevalence of epilepsy in the intellectu-
ally disabled population ranges between 14 and 44% depending upon case ascer-
tainment, with a proportional relationship with level of intellectual disability 
(Table  10.2) [6–11]. An overall prevalence of 22% has been shown based on a 
pooled meta-analysis of the data currently available [12].
Despite the clear relationship between epilepsy and intellectual disability 
understanding this association can be complex (Table 10.3). There may be a 
wide range of pathological processes influencing neurodevelopment at varying 
stages [25, 26]. This suggests multifactorial etiology which often results in 
multiple co-morbid conditions. People with intellectual disability and epilepsy 
have more physical co-morbidities than those with intellectual disability with-
out epilepsy, which results in higher health costs and increased mortality rates 
[27]. Intellectual disability in combination with epilepsy significantly raises 
standardized mortality ratios and the highest rates of mortality are associated 
with a high frequency of generalized seizures and profound intellectual dis-
ability [28]. In a UK investigation seizures and epilepsy were the most frequent 
cause of potentially avoidable hospital admissions in people with intellectual 
disability, equating to 40% of all emergency admissions in adults with 
Table 10.1 ILAE (2017) classification of seizure types [4]





Other motor (myoclonic, tonic, 
atonic, mixture)
Tonic-clonic
Other motor (myoclonic, tonic, 
atonic, mixture)
Non-motor Non-motor (absence) Unclassified
Focal to bilateral 
tonic-clonic
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intellectual disability [29]. Both epilepsy and intellectual disability are indi-
vidually associated with psychiatric co-morbidities. In people with intellectual 
disability and active epilepsy there is further increased risk of mental illness 
[30]. The assessment of behavior and neuropsychiatric side effects in people 
with epilepsy and intellectual disability can be complex and require a multi-
disciplinary approach.
People with intellectual disability and epilepsy are more likely to experience 
treatment resistant seizures with up to two-thirds showing a poor response to 






Table 10.3 Epilepsy syndromes and epilepsy phenotypes associated with intellectual disability
Syndrome
Genetic 








Febrile and non-febrile 
seizures in first 12 months of 
life
Episodes of status epilepticus










TSC1, TSC2 69% epilepsy [14]
Onset in infancy, 30% 
infantile spasms.
Infantile spasms-typical 
hypsarrhythmia EEG pattern 
[15]
May respond well to 
Vigabatrin [16]












T21 Two peaks in seizure 
onset-first year of life after the 
age of 40 [19]
Seizures may be associated 
with Alzheimer’s dementia-
generalized myoclonic 
seizures of high frequency and 
severity
Caution with AEDs with 
adverse cognitive profiles 









EEG findings-diffuse slow 
spike wave activity (≤2.5 Hz), 
with fast activity during sleep
ID and neuropsychiatric 
symptoms [20]
Rufinamide may offer 
most benefit [21]
Lamotrigine-improved 





in drop attacks [24]


















































anti-epileptic medication [8]. The combination of intellectual disability, treat-
ment resistant epilepsy, and neurological deficits is often associated with 
genetic abnormalities or underlying structural pathology [31]. Uncontrolled 
epilepsy can have serious negative consequences on both quality of life and 
mortality [32]. There is a limited evidence base to support the prescribing of 
anti-epileptic medication in this vulnerable population [33] Supporting people 
with intellectual disability and epilepsy especially those with poorly controlled 
epilepsy requires high levels of competence and confidence in staff in commu-
nity settings [34].
10.4  Diagnosis
Epilepsy is primarily a clinical diagnosis and should be made by a medical practi-
tioner with training and expertise in epilepsy. In order to establish a diagnosis of 
epilepsy a thorough history is required with good collateral information and witness 
reports of the event (Table 10.4). This is particularly important for people with intel-
lectual disability who may have cognitive and communication deficits. It is prefer-
able to obtain a detailed description of events including the pre-ictal, ictal, and 
post-ictal period. It is useful if this information is provided in a standardized way 
using validated seizure monitoring tools [35]. There may be benefit in video-record-
ing events. This will require the consent of the patient, or if the individual lacks 
capacity a formal review should take place with all interested parties to assess 
whether it is in the individuals best interests.
10.5  Differential Diagnosis
There are a wide range of events that can mimic the presentation of a seizure 
(Table 10.5). Identifying a seizure disorder in the intellectual disabled population is 
further complicated by levels of cognitive impairment, communication difficulties, 
and associate co-morbidities. People with epilepsy and intellectual disability have 
higher rates of stereotyped motor behaviors often associated with neurodevelop-
mental disorders such as autism [36]. It has been shown that up to 25% persons with 
intellectual disability and epilepsy referred to a specialist center have been misdiag-
nosed [37].
Table 10.4 Important aspects of Epilepsy history
Description of event—Pre-ictal, Ictal, Post-ictal (abnormal movements, abnormal tone, 
warning signs (aura), triggers, duration, day/nocturnal, frequency, any other events, injuries/
complications—e.g., head injury, difficulty breathing.
Inter-ictal changes—mood, personality, behavior.
Past history—previous seizures/progression of epilepsy, history of febrile seizures as a child, 
previous history of head injury, history of significant medical conditions, genetics, family 
history of epilepsy or neurological disorder.







































10.6  Epilepsy and Behavior
There are some key differences to be mindful of when considering the difference 
between a seizure and a behavioral disturbance. As a rule a seizure usually presents 
with similar behavior during each event. There is generally no clear precipitant and 
the individual will be unresponsive to attempts to communicate during the event. 
There is also the potential for behavioral or neuropsychiatric disturbance to occur as 
part of the complex epilepsy course. These symptoms may present during the peri-
ictal (pre-ictal, ictal, post-ictal) or inter-ictal period. There are added complexities 
to consider in the pharmacological management of epilepsy including the potential 
neuropsychiatric effects of AEDs, and the impact of psychotropic medications on 
seizure control.
10.7  Investigations
A special report by the UK chapter intellectual disability working group of the 
ILAE has shown that people with epilepsy and intellectual disability wait longer for 
routine investigations including EEG and MRI brain imaging [35]. This may be a 
result of inequality in access to specialist care provision [34]. Services need to 
ensure that the reasonable adjustments required are put in place so that this vulner-
able population have access to the relevant investigations required [35]. The use of 
video EEG alongside telemetry can be particularly helpful in differentiating sei-
zures from other behaviors in this population. It has been shown that there is a high 
rate of abnormality detection on MRI brain in those individuals with intellectual 
disability who undergo investigation [38].
It is important to note that a normal EEG between seizures does not rule out 
epilepsy. The ideal scenario is to capture an event during the EEG recording. The 
presence of epileptiform activity on EEG is also possible in people without epi-
lepsy, particularly people with intellectual disability [39]. MRI has essentially 
replaced CT as the imaging of choice for epilepsy because of its sensitivity and 
specificity in identifying structural lesions that could be the origin of epileptic 
Table 10.5 Differential diagnoses for seizures in people with intellectual disability
Cardiac—Syncope (vasovagal, orthostatic hypotension, arrhythmia)
Psychological—panic attack, dissociative disorder, psychosis, affective disorder, Non epileptic 
seizure
Behavioral disorder—stereotypies, sensory seeking behavior- including self-injurious 
behavior (SIB), compulsions
Vascular—migraine, transient ischemic attacks (TIA), transient global amnesia (TGA)
Metabolic—hypoglycemia, insulinoma, hypernatremia, hypocalcaemia
Sleep disorder—parasomnia, narcolepsy, enuresis, nightmares
Movement disorder—paroxysmal dyskinesia
Toxic state—alcohol, illicit substances, toxicity of prescribed medication








































discharges. However, MRI is not always widely available, and CT may be the 
most appropriate choice in an emergency. It is not uncommon for people with 
intellectual disability and associated co-morbidities to find it difficult to tolerate 
brain imaging. It may necessary to use sedation or even general anesthetic in order 
to complete investigations that require such an investigation in the person’s best 
interest. If this is the case then capacity of the individual to consent must be 
assessed. Where the individual lacks the capacity to make an informed decision 
there should be a formal best interest’s process as identified by the local legal 
processes weighing up the benefits and risks of such procedures and recorded 
accordingly. Electrocardiogram (ECG) and laboratory blood investigation are also 
an important part of the diagnosis process and will help rule out any potential 
other causes of events.
10.8  Treatment
A mainstay of epilepsy treatment is the prescription of AEDs. To date there is very 
little evidence-based research for AED prescribing in people with ID [33]. A 
Cochrane review into the pharmacological interventions for epilepsy in people with 
ID highlights the lack of evidence to support the efficacy, side-effect profile, and 
safety of AEDs for people with ID [40]. The treatment of epilepsy requires a person-
centered approach with consideration to each stage of the ILAE classification of 
epilepsies [4]. This is perhaps more relevant to the ID population where there will 
be particular concerns over the potential cognitive and behavioral side effects of 
AEDs.
10.8.1  Pharmacological Management
A large proportion of people with intellectual disability and epilepsy experience 
a chronic refractory course, with up to 40% receiving multiple AEDs but still 
experiencing poor seizure control [41]. In the UK the Royal College of 
Psychiatrists (RCPsych) College Report CR206 (2017) is a technical paper 
advising on the prescription of AEDs for people with epilepsy and intellectual 
disability, based on current evidence. This paper explores the potential for drug 
interactions, AED formulation, and the management of neuropsychiatric co-mor-
bidities. The College Report provides a simplified ‘traffic light system’ (first line, 
second line, and avoid) approach to AED prescription for people with intellectual 
disability.
The adverse effects of AEDs are more commonly observed when high doses are 
prescribed and dose titration is rapid [42]. Therefore it is recommended that AEDs 
are introduced at low dose and titration is slow, reducing the likelihood of dose 
related adverse effects. When adding a new drug it is recommended that a therapeu-
tic dose is established before removing the old drug. This will help attribute any 
changes in efficacy or side effect profile more easily [43].








































10.9  Lamotrigine (First Line)
Lamotrigine has been shown to be well tolerated in the intellectual disability popu-
lation, with good efficacy in seizure control and improvement on a range of quality 
of life measures [44]. Lamotrigine is known to have mood stabilizing properties and 
a randomized open-label investigation not only showed improved seizure control 
but improvements in challenging behavior [45]. There is specific evidence to show 
that Lamotrigine improves seizure control and a wide range of quality of life and 
social measures in people with Lennox-Gastaut syndrome [46].
10.10  Sodium Valproate (First Line)
The evidence suggests that valproate is a broad spectrum treatment option that can 
be used for a variety of seizure types with a good safety profile [47]. It is a first-line 
treatment for primary generalized seizures and is recommended for use for people 
with treatment resistant seizures, and people with intellectual disability may be 
more responsive [33]. The main limitations to the widespread use of valproate are 
the side effect profile. Along with more common effect such as weight gain, valpro-
ate is known to have significant teratogenic effects and is therefore not recom-
mended for women of child bearing age. This needs careful considerations in the 
intellectual disabled population for any women with borderline or mild intellectual 
disability who may be sexually active.
10.11  Topiramate (Second Line)
The efficacy of topiramate has been investigated through a number of randomized, 
placebo-controlled, add-on design trials. These investigations show good improve-
ments in seizure control, however the power of the studies is too low to demonstrate 
statistically significant findings. Importantly no significant effect on behavior was 
observed [48]. There is evidence that topiramate may be effective against a wide 
range of seizure types, particularly dangerous atonic seizures observed in Lennox-
Gastaut syndrome [49].
10.12  Levetiracetam (Second Line)
Levetiracetam appears to be generally well tolerated in the intellectual disabled 
population with improvement in seizure control and increased seizure freedom 
rates in open study designs [50]. An association between levetiracetam and neuro-
psychiatric side effects, particularly aggression has been observed, and these 
effects may be more common in people with intellectual disability [51]. As with 
most AEDs, the risk of neuropsychiatric side effects increases with a previous psy-
chiatric history [52].




































10.13  Carbamazepine (Second Line)
There is a very limited evidence base to support the efficacy of carbamazepine spe-
cifically in people with intellectual disability. There is evidence to suggest that slow 
release preparations may be better tolerated in the intellectual disabled population 
[53]. Carbamazepine in known to have a number of associated adverse effects includ-
ing hyponatremia, sedation, dizziness, and bone marrow suppression. Carbamazepine 
also interacts with many other drugs which can significantly alter their efficacy and 
requires consideration before prescribing [43]. Oxcarbazazepine has been investi-
gated in on add on trial in children with good efficacy but relatively poor tolerability 
with the need for dose reduction or discontinuation in one fifth of cases [54].
10.14  Lacosamide (Second Line)
An open label retrospective investigation suggests that lacosamide may be a useful 
adjunct for people with intellectual disability and treatment resistant epilepsy. However, 
the evidence base is very limited and caution is therefore advised with interpretation [55].
10.15  Perampanel (Second Line)
In a multi-center retrospective case series perampanel was found to be safe and well 
tolerated, with good improvement in seizure control as an adjunctive agent [56]. 
However, there is evidence to suggest an increased risk of psychiatric side effects in 
people with intellectual disability. A cross sectional study identified that over half of 
the patients involved experience behavioral changes, most notably aggression [57]. 
It is therefore advise that caution is taken if prescribing for individuals with a previ-
ous history of behavioral disorder or psychiatric illness.
10.16  AEDs to Avoid
Older AEDs such as phenobarbitone and phenytoin should not be prescribed for 
people with intellectual disability without good reason and only if it is in that indi-
viduals best interests. Such medications are associated with significant side effect 
profiles including a detrimental impact upon cognition, behavioral disturbance, 
multiple drug interactions, and encephalopathy at toxic levels [58].
10.17  Other AEDs
Newer AEDs have little to no evidence base for prescribing for people with epilepsy 
and intellectual disability. AEDs such as pregabalin, brivaracetam, tiagabine, and 
zonisamide may be used more routinely in clinical practice as second/third/fourth 

































line agents for treatment resistant seizures. However, efficacy, safety and tolerabil-
ity have yet to be rigorously assessed in this population.
The UK Ep intellectual disabilities—research Register is a National Institute of 
Health Research adopted project undertaking a retrospective cohort study of real 
world outcomes, including tolerability and efficacy of AEDs in people with epilepsy 
and intellectual disability [33]. A recent investigation into perampanel by the Register 
has highlighted that people with moderate to profound intellectual disability are less 
likely to drop out- possibly due to their inability to report or communicate subjective 
side effects. This lower dropout rate was associated with higher rates of seizure 
improvement due to higher rates of retention and compliance [56]. Health care profes-
sionals have a role in educating patients, caregivers and families to understand epi-
lepsy, the rationale for treatment, reduce stigma, and developing positive relationships. 
People with intellectual disability and their caregivers may not understand the impor-
tance of adhering to a treatment regime. A simple regime, the use of pictures and close 
liaison with the pharmacist all help. The use of pictures to communicate with people 
with intellectual disability can help such as the Books beyond words series [59].
10.18  Non-Pharmacological Interventions
10.18.1  Epilepsy Surgery
Intellectual disability is not, and should not be considered a contraindication for 
resective surgery [60]. In fact there is evidence to demonstrate that surgical inter-
vention can improve both the behavioral and cognitive functioning of some people 
with epilepsy and ID [61]. For people with intellectual disability and treatment 
resistant epilepsy surgical intervention has been associated with improvement in 
seizure freedom compared to medical treatment, alongside improved quality of life 
measures [62].
10.18.2  Vagus Nerve Stimulation
Vagus nerve stimulation is indicated for use as an adjunctive therapy and can reduce 
the frequency of seizures in adults who remain refractory with AED treatment, and 
are not suitable for resective surgery [63]. Vagus nerve stimulation is a relatively 
safe surgical intervention for patients with intellectual disability [64]. There are 
some important short and long-term effects of vagus nerve stimulation to consider 
including the potential for impact upon normal cardiac conduction [65].
10.18.3  Ketogenic Diet
A Ketogenic diet is essentially high in fat and low in carbohydrates. There is evi-
dence to support its efficacy in improving seizure control, specifically in Dravet 




































syndrome and Glut1 deficiency [66]. However, a Cochrane review of non-pharma-
cological interventions for adults with epilepsy and intellectual disability shows the 
lack of evidence available in this population. One of the main drawbacks of the diet 
is its tolerability [67].
10.19  Risk Management
The risks associated with epilepsy can be complex and wide ranging. We have 
to consider the impact of seizures themselves upon mortality, injury, and hospi-
talization. We also have to appreciate the wider impact of a chronic epilepsy 
course upon psychological, emotional, and social functioning. The approach to 
risk assessment and management should be person centered and evidence based. 
This will usually involve assessing the patient’s level of risk and depends on the 
individual, their environment, frequency and severity of epilepsy. There are cer-
tain risks that are increased with people with intellectual disability and it is 
important that healthcare professionals are aware of these higher risks and dis-
cuss them with the individual, their families and/or caregivers. Any assessment 
should also include a basic analysis of risk associated with bathing and shower-
ing, preparing food, using electrical equipment, managing prolonged or serial 
seizures, the impact of epilepsy in social settings, and the suitability of indepen-
dent living [68, 69].
10.20  Sudden Unexpected Death in Epilepsy (SUDEP)
Sudden unexpected Death in Epilepsy is the sudden and unexpected death of a 
person with epilepsy when no identifiable cause of death is made following post-
mortem examination and toxicology [70]. The diagnosis of SUDEP is not straight-
forward and is essentially one of exclusion. The classification of SUDEP has more 
recently been further refined [71]. The incidence of sudden death appears to be 20 
times higher in patients with epilepsy compared to the general population, and 
SUDEP is the most common cause of epilepsy related death [72]. The risk of 
SUDEP is increased for people with intellectual disability and treatment resistant 
epilepsy [73]. The UK NICE Clinical guidelines on the epilepsies [60] recom-
mend that patient’s, caregivers and families need to be counselled using informa-
tion tailored to the patient’s relative risk of SUDEP.  The SUDEP and Seizure 
Safety Checklist is an evidence based tool that can be used to both assess and 
communicate risk with patient, their families and caregivers [72]. Effectively 
assessing and managing risk factors using a person centered approach can reduce 
the number of epilepsy relate deaths in people with intellectual disability 
(Table 10.6) [74–76].





































10.21  Status Epilepticus
People with intellectual disability are more likely to experience status epilepticus 
and associated mortality rates are higher [78]. Status epilepticus is an emergency 
and may warrant the prescription of a rescue medication protocol to reduce the risk 
of potential harmful effects. Treatment should be given if the individual has a pro-
longed convulsive seizure that lasts for 5 min or more or if seizure occurs 3 or more 
times in an hour [60]. Rescue protocols can and should be adapted to ensure they are 
tailored specifically to an individual’s needs and identified risks. Standardized 
guidelines on training standards and practice are available from the Joint Epilepsy 
Council of the United Kingdom and Ireland. Any rescue medication must be admin-
istered by an appropriately trained person. Training should include an overview of 
epilepsy and associated risk factors in order to help ensure safe administration of 
rescue medication by family members or care staff. Treatment options available in 
the community include buccal midazolam (first-line treatment) and rectal diazepam 
(if midazolam is not suitable).
Benzodiazepines can be used as both rescue medication and as an effective add-
on treatment in refractory epilepsy. Clobazam in particular is recognized as being 
especially useful as intermittent rescue treatment, often used to manage cluster sei-
zures. Clobazam is considered appropriate to use regularly as second line or adjunct 
therapy for all major seizure types. A major concern is the development of toler-
ance, however around 30% of people with epilepsy prescribed clobazam could con-
tinue without experiencing long-term tolerance [33].
 Conclusion
The management of epilepsy in the intellectual disabled population is complex, 
not least owing to the level of cognitive impairment and communication difficul-
ties. The intellectual disabled population is more likely to have treatment resis-
tant epilepsy and multiple associated co-morbidities. Each case requires a person 
centered approach considering all aspects of epilepsy including seizures them-
selves, risk assessment, and the psychological and social impact of a multifacto-
Table 10.6 Desirable standards of care in the management of SUDEP [77]
•  Seizure frequency: maximize seizure control (GTC and nocturnal seizures) with 
pharmacological and non-pharmacological treatment. Aim for less than 3 seizures pre year.
•  Collateral risk: Work collaboratively with patient, families, and caregivers to deliver person 
centered risk reduction. Including advocating nocturnal supervision where indicated.
•  Access to care: Ensure equitable access to specialist review and reasonable adjustments for 
people with intellectual disability.
•  Comorbidities: Detailed assessment of physical and psychological co-morbidities including 
genetic testing, and liaison with relevant specialists.







































rial chronic disorder. The UK RCPsych has published two recent college reports 
detailing delivery of epilepsy care [79] and the approach to prescribing [43] for 
people with intellectual disability.
The delivery of epilepsy care to people with intellectual disability has been 
shown to be fragmented and at times inadequate due to inequalities in access to 
specialist care [34]. There is a need for improved collaboration between all pro-
fessional bodies involved in the delivery of care to this population, with improve-
ment in standards of assessment, information gathering, and the education and 
training of healthcare staff, families or caregivers [35].
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